General Information of Drug Combination (ID: DCWDKRP)

Drug Combination Name
BIO-300 Bleomycin
Indication
Disease Entry Status REF
Glioma Investigative [1]
Component Drugs BIO-300   DMJ7NVI Bleomycin   DMNER5S
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: SF-295
Zero Interaction Potency (ZIP) Score: 7.31
Bliss Independence Score: 5.66
Loewe Additivity Score: 6.03
LHighest Single Agent (HSA) Score: 11.1

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of BIO-300
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
Rheumatoid arthritis FA20 Phase 1 [3]
Indication(s) of Bleomycin
Disease Entry ICD 11 Status REF
Cervical cancer 2C77.0 Approved [4]
Head and neck cancer 2D42 Approved [4]
Hodgkin lymphoma 2B30 Approved [5]
Penile cancer N.A. Approved [4]
Testicular germ cell tumor N.A. Approved [4]
Classic Hodgkin lymphoma N.A. Investigative [4]
Follicular lymphoma 2A80 Investigative [4]
Bleomycin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Breaker [10]
------------------------------------------------------------------------------------
Bleomycin Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Bleomycin hydrolase (BLMH) DECH1VP BLMH_HUMAN Metabolism [11]
------------------------------------------------------------------------------------
Bleomycin Interacts with 41 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Bleomycin hydrolase (BLMH) OT2QPWQJ BLMH_HUMAN Affects Response To Substance [12]
Superoxide dismutase (SOD1) OT39TA1L SODC_HUMAN Increases Expression [13]
Catalase (CAT) OTHEBX9R CATA_HUMAN Increases Expression [13]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Increases Expression [13]
Interstitial collagenase (MMP1) OTI4I2V1 MMP1_HUMAN Increases Expression [14]
Granulocyte-macrophage colony-stimulating factor (CSF2) OT1M7D28 CSF2_HUMAN Increases Expression [14]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [14]
C-X-C motif chemokine 2 (CXCL2) OTEJCYMY CXCL2_HUMAN Increases Expression [14]
Mucin-5AC (MUC5AC) OTJV8O04 MUC5A_HUMAN Increases Expression [14]
Proheparin-binding EGF-like growth factor (HBEGF) OTLU00JS HBEGF_HUMAN Increases Expression [14]
Transmembrane protein 250 (TMEM250) OTLJ4G5G TM250_HUMAN Increases Expression [6]
Suppressor of cytokine signaling 1 (SOCS1) OTWA9KFU SOCS1_HUMAN Decreases Expression [15]
Serine/threonine-protein kinase Chk2 (CHEK2) OT8ZPCNS CHK2_HUMAN Increases Phosphorylation [16]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Increases Expression [7]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Increases Expression [17]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Expression [7]
Fibronectin (FN1) OTB5ZN4Q FINC_HUMAN Increases Expression [7]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [18]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Increases Expression [7]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [19]
Cathepsin S (CTSS) OT3PXIPM CATS_HUMAN Increases Expression [20]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Increases Phosphorylation [21]
Max-interacting protein 1 (MXI1) OTUQ9E0D MXI1_HUMAN Decreases Expression [6]
Actin, aortic smooth muscle (ACTA2) OTEDLG8E ACTA_HUMAN Increases Expression [7]
Unconventional myosin-Ie (MYO1E) OTM9YSIZ MYO1E_HUMAN Decreases Expression [6]
Transcription intermediary factor 1-beta (TRIM28) OTE38OBF TIF1B_HUMAN Increases Phosphorylation [16]
Serine-protein kinase ATM (ATM) OTQVOHLT ATM_HUMAN Increases Phosphorylation [16]
Structural maintenance of chromosomes protein 1A (SMC1A) OT9ZMRK9 SMC1A_HUMAN Increases Phosphorylation [16]
7SK snRNA methylphosphate capping enzyme (MEPCE) OTRBQEYP MEPCE_HUMAN Increases Expression [6]
Transmembrane protein 87A (TMEM87A) OT8ATDVX TM87A_HUMAN Increases Expression [6]
Terminal nucleotidyltransferase 4B (TENT4B) OTUF6FWW PAPD5_HUMAN Decreases Expression [6]
Lipase member H (LIPH) OTRGYLKL LIPH_HUMAN Decreases Expression [6]
Abasic site processing protein HMCES (HMCES) OTVRDL6U HMCES_HUMAN Decreases Expression [6]
Small integral membrane protein 14 (SMIM14) OT47IF19 SIM14_HUMAN Decreases Expression [6]
Kelch-like protein 42 (KLHL42) OTK6WARI KLH42_HUMAN Increases Expression [6]
Inactive cell surface hyaluronidase CEMIP2 (CEMIP2) OT9I1XUO CEIP2_HUMAN Decreases Expression [6]
ERBB receptor feedback inhibitor 1 (ERRFI1) OT7VZ2IZ ERRFI_HUMAN Decreases Expression [6]
Transmembrane and coiled-coil domain protein 3 (TMCC3) OTAIQ6V6 TMCC3_HUMAN Decreases Expression [6]
Lactosylceramide alpha-2,3-sialyltransferase (ST3GAL5) OT27CCUF SIAT9_HUMAN Decreases Expression [6]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Decreases Response To Substance [22]
DNA cytosine-5)-methyltransferase 1 (DNMT1) OTM2DGTK DNMT1_HUMAN Affects Response To Substance [23]
------------------------------------------------------------------------------------
⏷ Show the Full List of 41 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult acute myeloid leukemia DCO50A4 HL-60(TB) Investigative [1]
Adult T acute lymphoblastic leukemia DCMV8BE MOLT-4 Investigative [1]
Anaplastic large cell lymphoma DCRJHOG SR Investigative [1]
Astrocytoma DC304HQ U251 Investigative [1]
Astrocytoma DC8ZIGX SNB-19 Investigative [1]
Childhood T acute lymphoblastic leukemia DCZ6DFM CCRF-CEM Investigative [1]
Chronic myelogenous leukemia DC2YPZ8 K-562 Investigative [1]
Clear cell renal cell carcinoma DCNHC16 786-0 Investigative [1]
Clear cell renal cell carcinoma DC6NHMT A498 Investigative [1]
Clear cell renal cell carcinoma DC354OV TK-10 Investigative [1]
Clear cell renal cell carcinoma DCMFEJO CAKI-1 Investigative [1]
Glioblastoma DCQ8K11 SNB-75 Investigative [1]
Glioma DCCEQYH SF-268 Investigative [1]
Glioma DCGKGRE SF-539 Investigative [1]
Papillary renal cell carcinoma DCYSK81 ACHN Investigative [1]
Renal cell carcinoma DCUUJ47 SN12C Investigative [1]
Breast adenocarcinoma DCEC6CR MDA-MB-468 Investigative [24]
Colon adenocarcinoma DC2VSQR COLO 205 Investigative [24]
Colon carcinoma DC3D7EE KM12 Investigative [24]
Invasive ductal carcinoma DC01CJE BT-549 Investigative [24]
Invasive ductal carcinoma DCXWR0K HS 578T Investigative [24]
Adenocarcinoma DC2JRFI DU-145 Investigative [25]
Adenocarcinoma DC85IU0 OVCAR3 Investigative [25]
Adenocarcinoma DC9OOHQ A549 Investigative [25]
Adenocarcinoma DCSDYQA HCT116 Investigative [25]
Adenocarcinoma DCSFYUI SW-620 Investigative [25]
Adenocarcinoma DC13147 HCT-15 Investigative [25]
Adenocarcinoma DCTO54C HCC-2998 Investigative [25]
Amelanotic melanoma DC0OCST M14 Investigative [25]
Cutaneous melanoma DCWPQXH SK-MEL-28 Investigative [25]
Cutaneous melanoma DC6NCGE SK-MEL-5 Investigative [25]
High grade ovarian serous adenocarcinoma DCRZPG9 OVCAR-5 Investigative [25]
High grade ovarian serous adenocarcinoma DC2JP98 OVCAR-8 Investigative [25]
Large cell lung carcinoma DCS8V89 NCI-H460 Investigative [25]
Lung adenocarcinoma DCMXPAB HOP-62 Investigative [25]
Lung adenocarcinoma DCZSDMS EKVX Investigative [25]
Malignant melanoma DC4VNHN UACC62 Investigative [25]
Malignant melanoma DCJNYPK LOX IMVI Investigative [25]
Melanoma DC01PE4 UACC-257 Investigative [25]
Melanoma DCWAAN5 SK-MEL-2 Investigative [25]
Melanoma DCFOYZN MALME-3M Investigative [25]
Mixed endometrioid and clear cell carcinoma DC43L41 IGROV1 Investigative [25]
Ovarian serous cystadenocarcinoma DCPTKQN SK-OV-3 Investigative [25]
------------------------------------------------------------------------------------
⏷ Show the Full List of 43 DrugCom(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Clinical pipeline report, company report or official report of Humanetics.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Bleomycin FDA Label
5 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
6 Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells. Arch Toxicol. 2021 May;95(5):1631-1645. doi: 10.1007/s00204-021-03014-2. Epub 2021 Mar 26.
7 Pulmonary fibrosis model using micro-CT analyzable human PSC-derived alveolar organoids containing alveolar macrophage-like cells. Cell Biol Toxicol. 2022 Aug;38(4):557-575. doi: 10.1007/s10565-022-09698-1. Epub 2022 Mar 10.
8 An antisense oligonucleotide targeted to human Ku86 messenger RNA sensitizes M059K malignant glioma cells to ionizing radiation, bleomycin, and etoposide but not DNA cross-linking agents. Cancer Res. 2002 Oct 15;62(20):5888-96.
9 XRCC1 deficiency sensitizes human lung epithelial cells to genotoxicity by crocidolite asbestos and Libby amphibole. Environ Health Perspect. 2010 Dec;118(12):1707-13. doi: 10.1289/ehp.1002312. Epub 2010 Aug 11.
10 Bleomycin and talisomycin sequence-specific strand scission of DNA: a mechanism of double-strand cleavage. Cancer Res. 1982 Jul;42(7):2779-85.
11 The C-terminus of human bleomycin hydrolase is required for protection against bleomycin-induced chromosomal damage. Mutat Res. 1998 Oct 12;421(1):1-7.
12 Genetic polymorphisms of DNA repair and xenobiotic-metabolizing enzymes: role in mutagen sensitivity. Carcinogenesis. 2002 Jun;23(6):1003-8. doi: 10.1093/carcin/23.6.1003.
13 Age-dependent basal level and induction capacity of copper-zinc and manganese superoxide dismutase and other scavenging enzyme activities in leukocytes from young and elderly adults. Am J Pathol. 1993 Jul;143(1):312-20.
14 Agents associated with lung inflammation induce similar responses in NCI-H292 lung epithelial cells. Toxicol In Vitro. 2008 Oct;22(7):1782-8.
15 Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling. Mutat Res. 2007 Jun 1;619(1-2):16-29. doi: 10.1016/j.mrfmmm.2006.12.007. Epub 2007 Feb 8.
16 Direct activation of ATM by resveratrol under oxidizing conditions. PLoS One. 2014 Jun 16;9(6):e97969. doi: 10.1371/journal.pone.0097969. eCollection 2014.
17 Enhanced IL-1 beta and tumor necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J Immunol. 1993 May 1;150(9):4188-96.
18 Synergistic anticancer activity of dietary tea polyphenols and bleomycin hydrochloride in human cervical cancer cell: Caspase-dependent and independent apoptotic pathways. Chem Biol Interact. 2016 Mar 5;247:1-10. doi: 10.1016/j.cbi.2016.01.012. Epub 2016 Jan 29.
19 Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexes. Biochem Pharmacol. 2014 Oct 1;91(3):312-22. doi: 10.1016/j.bcp.2014.08.006. Epub 2014 Aug 15.
20 Radiation-induced cathepsin S is involved in radioresistance. Int J Cancer. 2009 Apr 15;124(8):1794-801. doi: 10.1002/ijc.24095.
21 Bleomycin-induced nuclear factor-kappaB activation in human bronchial epithelial cells involves the phosphorylation of glycogen synthase kinase 3beta. Toxicol Lett. 2009 Jun 22;187(3):194-200. doi: 10.1016/j.toxlet.2009.02.023. Epub 2009 Mar 13.
22 Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res. 2000 May;6(5):1796-803.
23 DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol. 2008 Jan;28(2):752-71. doi: 10.1128/MCB.01799-07. Epub 2007 Nov 8.
24 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
25 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.